Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients With Active Psoriatic Arthritis. J of Skin 2020, 4 (5), s43. https://doi.org/10.25251/skin.4.supp.43.